AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-23. (Cancelled)

24. (Currently amended) A recombinant mammalian animal cell transformed with a baculovirus p35 gene encoding a protein that inhibits caspase activity and/or potentiates protein biosynthesis, and a gene encoding for a protein selected from the group consisting of ecarin, fibrinogen, and blood coagulation factor VIII.~~, comprising an animal cell that has been obtained from a mammal and has been transformed with a gene encoding a production amount potentiating factor that has been introduced into the animal cell, wherein the production amount potentiating factor is a factor having caspase activity inhibiting activity and/or protein biosynthesis activity potentiating action and said gene encoding the factor having caspase activity inhibiting activity and/or protein biosynthesis activity potentiating action consists of a baculovirus P35 gene, and the protein expressed by said transformed cell is one selected from the group consisting of ecarin, fibrinogen, and blood coagulation factor VIII.~~

25-29. (Cancelled)

30. (Previously presented) The recombinant animal cell according to claim 24, wherein the animal cell is selected

from the group consisting of a Chinese hamster ovary cell (CHO cell), a mouse myeloma cell, a BHK cell, a 293 cell, and a COS cell.

31. (Previously presented) The recombinant animal cell according to claim 30, wherein the animal cell is any one of a Chinese hamster ovary cell (CHO cell) DG44 strain, a BHK21 strain, and a mouse myeloma SP2/0 strain.

32. (Currently amended) The recombinant animal cell according to claim ~~25~~24, ~~wherein~~ comprising an expression vector for expressing ~~a gene encoding both or any one of the protein production gene and the production amount potentiating factor~~ the baculovirus p35 gene and the gene encoding the protein selected from the group consisting of ecarin, fibrinogen, and blood coagulation factor VIII, wherein the expression vector ~~having~~ contains a promoter selected from the group consisting of a SV40 early promoter, a SV40 late promoter, a cytomegalovirus promoter and a chicken β-actin promoter, as well as a marker gene selected from the group consisting of an aminoglycoside 3′ phosphotransferase (neo) gene, a puromycin resistant gene, a dihydrofolate reductase (dhfr) gene, and a glutamine synthesis enzyme (GS) gene.

33. (Currently amended) The recombinant animal cell according to claim 24, ~~wherein~~ comprising an expression vector

having a chicken β-actin promoter and ~~a~~ the baculovirus P35 gene ~~is used~~.

34. (Currently amended) The recombinant animal cell according to claim 24, ~~characterized in that~~comprising an expression vector having a cytomegalovirus enhancer and ~~a~~ the baculovirus P35 gene ~~is used to introduce the gene into the animal cell~~.

35. (Previously presented) The recombinant animal cell according to claim 24, wherein the protein to be produced is a secretion protein.

36. (Previously presented) The recombinant animal cell according to claim 35, wherein the protein to be produced is ecarin.

37. (Previously presented) The recombinant animal cell according to claim 24, wherein the protein to be produced is a protein present in blood.

38. (Previously presented) The recombinant animal cell according to claim 35, wherein the protein to be produced is fibrinogen.

39. (Previously presented) The recombinant animal cell according to claim 35, wherein the protein to be produced is blood coagulation factor VIII.

40. (Cancelled)

41. (Previously presented) A method for mass-producing a protein, said method comprising culturing the recombinant animal cell according to claim 24 under a culture condition so that apoptosis is not induced.

42. (Previously presented) The method according to claim 41, wherein the culturing method is any one of a fed batch culturing method, a perfusion culturing method, and a culturing method using a nutrient-enriched medium.

43. (Previously presented) The method according to claim 41, wherein a serum-free medium is used.

44. (Previously presented) The method according to claim 41, wherein the protein has a production amount, which can be increased up to about 4,000 μg/ml.

45. (Currently amended) A method for preparing the recombinant animal cell according to claim ~~25~~24, wherein the animal cell is transformed in such a manner that ~~a protein production gene and a gene encoding a production amount potentiating factor~~ the baculovirus p35 gene and the gene encoding for a protein selected from the group consisting of ecarin, fibrinogen, and blood coagulation factor VIII are introduced into the animal cell simultaneously or at different times.

46. (Cancelled)